SoGAT XVII/Paris, 2004 Proficiency Testing of In-House Developed HIV-1 NAT for Blood Screening Michael Chudy, Paul-Ehrlich-Institut Division of Virology,

Slides:

Advertisements

Similar presentations

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.

Advertisements

Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.

NIBSC Multiplex Proficiency Panel - A multicentre study

National Institute for Biological Standards and Control Assuring the quality of biological medicines Proposal for a Hepatitis A genotype panel Rob Anderson.

The Sense of Sensitivity I Dr. Matthias Gessner Plasma Control Europe/Plasma Analytics Baxter AG, Vienna.

Improved Reflexive Testing Algorithm for Hepatitis C Infection Using Signal-to-Cutoff Ratios of a Hepatitis C Virus Antibody Assay K.K.Y. Lai, M. Jin,

PCS Conference Reducing Inhibition of RT-PCR in plasma samples from cadavers Dr Simon Carne National Transfusion Microbiology Reference Laboratory (NTMRL)

Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.

Paris, May 2004SoGAT XVII SoGAT and the Development of Standards Harvey Holmes Division of Retrovirology NIBSC, UK.

Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:

Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA

XVIII SoGAT Washington 24 May 2005 SoGAT and HIV NAT Standards - 2 nd International Standard for HIV-1 RNA Harvey Holmes*, Clare Davis* and Alan Heath**

Alere TM HIV Combo Yuko Tamanoue, Product Development Department.

PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.

Generic Automated Sample Preparation for Commercial NAT Assays

Pooled Source Plasma NAT for HIV-1 An Update from the Bayer HIV-1 IND Study Barbara Masecar Bayer Corporation Raleigh, NC Blood Products Advisory Committee.

BioLife Plasma Services Experience with HBV NAT Testing

1 HBV Genotype Panel Michael Chudy Section of Molecular Virolgy Division of Virology SoGAT XXI Meeting Brussels, May 2009.

HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.

Update on CBER HIV NAT panels and International panels Indira Hewlett, Ph.D Chief, Lab. of Molecular Virology DETTD/OBRR/FDA May 28, 2009 XXI SoGAT meeting.

FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.

Hepatitis E Virus – Progress in Standardization of NAT-Based Assays Blood Products Advisory Committee Rockville, 20 th September 2012 Sally.

Update on the Replacement of the HCV RNA International Standard Sally Baylis & Alan Heath, NIBSC SoGAT XX, Warsaw June 2007.

SOGAT Validation of HCV-RNA detection in small test pools on cadaveric samples Marco Koppelman #, Theo Cuypers #, Mirjam de Waal #, Maarten.

Michael Chudy, Paul-Ehrlich-Institut SoGAT XVIII, Bethesda MD

CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.

EQASs for Blood Borne Virus Genomes and BSE Prions from Cattle Brain and INSTAND Reference Materials H.-P. Grunert 1,2, K.-O. Habermehl 1,2, V. Lindig.

E A 1 Parvovirus B19 and HAV Screening of Whole Blood Donations SL Stramer, KL Kane, ML Beyers, RY Dodd, American Red Cross and RIF Smith, National.

Parvovirus B19 Genotype 2 Plasma, Sourced from the US Dr Sally A. Baylis, Division of Virology NIBSC.

Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.

Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.

Sensitivity of NAT blood screening assays in performance evaluation and proficiency programs Harry van Drimmelen, Nico Lelie, (VQC-Sanquin) and the principal.

NAT Detection of Blood Borne Viral Markers in Tissues from Cadaver Donors John Saldanha 1 and David Padley 2 1 Canadian Blood Services, Ottawa, Canada.

Monitoring the Performance of Nucleic Acid Tests using Data Generated from EDCNet and DigitalPT Wayne Dimech, Darren Jardine, Thu-Anh Pham and the staff.

1 Procleix ® WNV Assay: A TMA-based Assay for Screening Blood Donations for West Nile Virus RNA Jeff Linnen, Ph.D. Research and Development Gen-Probe Incorporated,

National Institute for Biological Standards and Control Assuring the quality of biological medicines Human Cytomegalovirus (HCMV) Proposed 1 st International.

SoGAT June 14, 2006 HCV-RNA and HIV-RNA detection in small test pools of cadaveric samples for viral safety of tissue transplants Maarten Koot#,

1 B19 Testing of Plasma for Fractionation: Current Thinking Mei-ying W Yu, PhD Division of Hematology CBER/FDA SoGAT XVII May 26-27, 2004.

SoGAT, Berne 2006BTS SRC Berne Ltd. Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd. Dr. Martin Stolz.

History of ILC Involvement in NAT Standardization 1998: Inter-Organization Discussion for the Establishment of Standard Reference Material for Nucleic.

Blood Products & related Biologicals: SoGAT, 28 May 09 1 |1 | Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines and Pharmaceutical.

Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.

NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.

Elisa Moretti Process and Analytical Development KEDRION S.p.A SoGAT XVI Paul Ehrlich Institut - Langen, Germany 3 rd July 2003 Automated Extraction for.

Preparation of HBV DNA reference standards and the experience of HBV NAT in Taiwan Dr. Hwei-Fang Cheng Department of Health, Taiwan.

Serology - anti-HCV. anti-HIV, HBsAg NAT - HCV RNA - since 2000

DISCONTINUATION OR NO DISCONTIUNATION: COMPARISON OF SINGLE UNIT HIV ANTIGEN TESTING VS. POOLED NAT TESTING Gerald Schochetman, Ph.D. Abbott Laboratories.

An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.

CE mark issues -- PEI view

DRK-Blutspendedienst West  nPrecipitation steps (PEG), centrifugation and careful resuspension of the invisible pelleted viral particles precede efficient.

DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern Experience with Roche´s COBAS AmpliPrep/COBAS TaqMan96 automated PCR system in two large.

February 24, 2016 | 1 Paul Strengers MD, FFPM Sanquin Blood Supply Amsterdam The Netherlands Risk assessment schemes: Impact of.

CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.

SoGAT May 2005 Are conversion factors to international units assay related? Marco Koppelman, Henk Reesink, Nico Lelie, Theo Cuypers.

Progress on Study to Validate Synthetic Materials for Use as Calibrators and References SoGAT XIX Bern, 14 June 2006 Roberta M. Madej Roche Molecular Diagnostics.

Relative Sensitivities of US Licensed NAT Assays for Detection of Viremia in Early HIV and HCV Infection MP Busch, SA Glynn, DJ Wright, D Hirschkorn, ME.

SOGAT Presence (absence) of genotype 2 and 3 Erythrovirus DNA in manufacturing plasma Theo Cuypers, Marco Koppelman, Margret Sjerps, Henk Reesink.

Dawit Assefa Ethiopia Health and Nutrition Research Institute Dawit Assefa Ethiopia Health and Nutrition Research Institute Evaluation of an in-house HIV.

Saeko Mizusawa, Yoshiaki Okada

Harvey Holmes, Clare Morris and Neil Berry Division of Retrovirology

Tom Øystein Jonassen, Mona Holberg-Petersen, Einar S. Berg

Evaluation data on the new Roche cobas s 201 system with the cobas TaqScreen MPX test Lutz Pichl, Volkmar Schottstedt German Red Cross Blood Transfusion.

Evaluation of Candidate Standard XX (97/650)

K.H. Buchheit, A. Daas, C.M. Nübling, J.M. Spieser 3 July 2003

Italian EQA study for HCV RNA, HIV RNA and HBV DNA G. M. Bisso, K

Viral Safety of Blood Products in Taiwan

1st International Standard for HIV-1 RNA NIBSC Code 97/656

Distributions of parvovirus B19 genotype 1-3 in blood donations

SoGAT Meeting, Berne, 14 June 2006 M. Nübling (PEI, Germany)

SoGAT meeting XXI May (2009), Brussels, Belgium

Presentation transcript:

SoGAT XVII/Paris, 2004 Proficiency Testing of In-House Developed HIV-1 NAT for Blood Screening Michael Chudy, Paul-Ehrlich-Institut Division of Virology, Section of Molecular Pathology Langen, Germany;

German Regulations for Blood Components and FFP: Implementation of HIV-1 NAT  BAnz. [Fed. Gazette] No 90, 9506; 05/16/2001  detection limit of HIV-1 RNA: 10,000 IU/ml for single donation  prospective implementation 01/01/2002  08/27/2001: PEI announcement  HIV-1 subtypes: M group  PEI collaborative study of in-house NAT assays for detection of HIV-1 and HCV RNA; participation on voluntary basis (10/01/2001)  HIV-1 NAT implementation postponed PEI

Collaborative Study: In-house NAT Assays PEI

Collaborative Study 2001: Conclusions  HCV NAT (in-house):  homogeneous results (sensitivity, specificity, and proficiency)  no differences between SD- and MP-testing  HIV-1 NAT (in-house):  results less homogeneous  further improvements and validation  regular proficiency studies for in-house NAT assays organised by PEI  acceptance: successful participation PEI

German Regulations for Blood Components and FFP: Implementation of HIV-1 NAT  BAnz. [Fed. Gazette] No 103, 12269; 06/05/2003  implementation 05/01/2004  validation of in-house assays  acceptance of in-house assays: successful participation in PEI proficiency study PEI

Proficiency Study for In-house HIV-1 NAT Assays: : Objective Evaluation of in-house NAT assays for detection of HIV-1 in blood donations:  analytical sensitivity  subtype sensitivity  specificity  proficiency PEI

Proficiency Study for In-house HIV-1 NAT Assays: Study Design Focus on the detection limit: 10,000 IU HIV1-RNA/ml single donation Materials Reference preparations (WHO: 31,600, 10,000 2x, 3,160 IU/ml/PEI: 10,000 IU/ml) HIV-1 subtypes (A, C, CRF_AE, G, H; each 10,000 IU/ml) NHP pool (2x) Simulation of the pool size (volume, dilution) Lab and sample encoding Samples frozen at -80°C/shipment on dry ice Results: reactive/non-reactive (data sheet) PEI

Proficiency Study for In-house HIV-1 NAT Assays: Participants Overall 30 participants  29 labs: blood screening; 2 labs only pooling/1 lab: manufacturer of plasma prod.  SD 1x; MP-8 1x; MP-10 3x; MP-15 2x, MP-20 4x, MP-24 2x, MP-40 1x, MP-48 5x; and MP x  7 labs with virus enrichment  NA extraction: 14 labs Qiagen/5 labs Roche/4 labs NucliSens/5 labs other  23 real-time PCR (20x TaqMan/3x LC Hybr.)  2x CA HIV-1 Monitor/3x RT-PCR +Gene Scanning PEI

Proficiency Study In-house HIV-1 NAT: Results

Proficiency Study for In-house HIV-1 NAT Assays (2003): Conclusions PEI Results more homogeneous compared to the results of the study in 2001 No differences in respect with the used pool size Due to the test results, 2 test labs switched to commercial assays Assessment of in-house assays: validation studies and successful participation in proficiency study Conclusion: In-house assays are suitable for blood screening CE-marking of in-house assays: open question